Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2021 financial results on November 4, 2021, after market close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET. Interested parties can access the webcast via the company’s investors' section. Dynavax is known for developing HEPLISAV-B, a hepatitis B vaccine, and is advancing its CpG 1018 adjuvant through research collaborations targeting vaccines for various diseases.

Positive

• Dynavax's confirmed date for Q3 2021 financial results may provide insights into its financial health and operational progress.
• Strong potential for growth as Dynavax collaborates on vaccines for COVID-19 and other infectious diseases.

Negative

• None.

EMERYVILLE, Calif., Oct. 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, will report third quarter 2021 financial results on Thursday, November 4, 2021, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, November 4, 2021 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 5994808.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis, plague and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts: 
Nicole Arndt, Investor Relations 
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2021-financial-results-and-host-conference-call-on-november-4-2021-301405588.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its Q3 2021 financial results?

Dynavax will report its Q3 2021 financial results on November 4, 2021, after market close.

What is the time for the Dynavax conference call?

The conference call will take place on November 4, 2021, at 4:30 p.m. ET.

How can I access the Dynavax financial results webcast?

The webcast can be accessed through the 'Events & Presentations' page in the Investors section of Dynavax's website.

What products does Dynavax have on the market?

Dynavax's first commercial product is HEPLISAV-B, a hepatitis B vaccine approved in the U.S. and EU.

What collaborations is Dynavax currently involved in?

Dynavax is advancing its CpG 1018 adjuvant through collaborations focused on vaccines for COVID-19, pertussis, and flu.